MZ: Meso-Zeaxanthin; L: Lutein; RZ: RR-Zeaxanthin; AMD: Age-related Macular Degeneration; MD: Macular Degeneration; NAFL: Non-Alcoholic Fatty Liver; NASH: Nonalcoholic Steatohepatitis; DPPH: Diphenyl-2-Picrylhydrazyl; ABTS: 2, 2’-Azino-Bis (3-Ethylbenzothiazoline-6-Sulfonic acid); GST: Glutathione-S-Transferase; UDPGT: Uridine Diphosphate Glucuronyl Transferase; SGOT: Serum glutamic oxaloacetic...

BACKGROUND AND AIM The etiology of non-alcoholic fatty liver disease (NAFLD) progression, and why some patients develop non-alcoholic steatohepatitis (NASH) vs. uncomplicated NAFLD, is not well understood. Obesity and NAFLD are thought to be associated with high circulating levels of leptin; however, the role of leptin in NASH has been controversial. Secondly, as ob/ob mice are known to have el...

Glucagon‑like peptide‑1 (GLP‑1) is involved in the development of non‑alcoholic steatohepatitis (NASH), which is characterized by fatty acid imbalance. The aim of this study was to investigate the effects of the GLP‑1 receptor (GLP‑1R) agonist, exendin‑4 (Ex‑4), on hepatic fatty acid metabolism and its key enzyme, Δ‑5‑desaturase, in a murine model of NASH. NASH was induced in db/db mice fed a m...

Chronic liver injury, as observed in non-alcoholic steatohepatitis (NASH), progressive fibrosis, and cirrhosis, remains poorly treatable. Steatohepatitis causes hepatocyte loss part by a direct lipotoxic insult, which is amplified derangements the non-parenchymal cellular (NPC) interactive network wherein hepatocytes reside, including, hepatic stellate cells, sinusoidal endothelial cells macrop...

Non-alcoholic steatohepatitis (NASH) is a clinically serious stage of non-alcoholic fatty liver disease (NAFLD). Histologically characterized by hepatocyte ballooning, immune cell infiltration, and fibrosis, NASH, at molecular level, involves lipid-induced death cytokine production. Currently, there are very few diagnostic biomarkers available to screen for no pharmacological intervention its t...

Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disease, coupled with metabolic syndrome, which may progress to non-alcoholic steatohepatitis (NASH). Diabetes, obesity, hypertension, hypercholesterolemia, and hypertriglyceridemia are considered to be the most common causes leading to the incidence of NAFLD. It is assumed that the accumulation of lipid deposits in hepato...

Non-alcoholic steatohepatitis (NASH) is a common liver disorder caused by fatty liver. Because NASH is associated with fibrotic and morphological changes in liver tissue, a direct imaging technique is required for accurate staging of liver tissue. For this purpose, in this study we took advantage of two label-free optical imaging techniques, second harmonic generation (SHG) and auto-fluorescenc...

The natural polyphenol compound resveratrol (RSV) is considered to have a broad spectrum of beneficial biological activities upon human health. However, the exact effect of RSV on steatosis (a phenotype of non-alcoholic fatty liver [NAFL]) or fibrosis and inflammation (major phenotypes of non-alcoholic steatohepatitis [NASH]) is not known. Our data showed that administration of RSV (2 or 20 mg/...

context non-alcoholic fatty liver disease (nafld) is a chronic liver disease, with 5-10% of liver having extra fat. increase in its prevalence in all age groups is linked with obesity and type ii diabetes. the treatment of nafld remains controversial. a growing body of evidence suggests a relation between overgrowth of gut microbiota with nafld and non-alcoholic steatohepatitis (nash). the obje...

The high prevalence of non-alcoholic fatty liver disease (NAFLD) has made the condition an important public health issue. Two clinical entities are manifestations of NAFLD, namely, non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). The former tends to be benign and non-progressive while the latter can progress to cirrhosis, which in rare cases gives rise to hepatocellula...